'Why are you not prepared to pay $5 for wanton mee?' – Minister's comments spark outrage from netizens
Inflation and the rising cost of living has hit all of us hard – not just locally, but globally, too. Even with the government's announcement of measures such as CDC Vouchers, it's difficult not to feel the sting on our wallets when everything costs nearly twice as much as it used to, compared to a decade ago.
On a recent podcast from CNA (Channel NewsAsia), hosts Steven Chia and Crispina Robert sat down with Sustainability and Environment Minister, Grace Fu, for a conversation about hawker centres – and one particular comment from Minister Fu ignited a firestorm online.
The hosts discussed how they felt very sad when their favourite hawker retired or closed their stalls as they didn't have successors. Crispina said, 'Alongside infrastructure, this is the main challenge, right?' to which Minister Fu replied that the livelihood of a hawker is not something Singapore's younger generation would aspire to. They are well-educated, and 'there's actually better livelihoods besides being a hawker.'
She continued by saying that Singaporeans needed to think about how to treat their hawkers better, and if there was a better way to share food costs. 'I always think that if you're prepared to pay S$18 or S$20 for a pasta, why are you not prepared to pay S$5 for wanton mee? So sometimes we expect too much from our hawkers as well,' she said. 'They actually don't raise their prices often. They don't raise it every year. Their costs have gone up.'
This ignited a firestorm of angry responses from netizens. Many comments blasted Minister Fu for being 'out of touch', and some also asked if she had eaten at a hawker centre recently. The cost of rental was also repeatedly highlighted, with several saying it was a main factor for rising prices.
Another netizen commented that while they did agree that hawkers needed to raise their prices in order to have a sustainable livelihood, they also said that it was likely all the money would be 'sucked by landlords'.
Yet another said that due to the government constantly framing hawker food as 'cheap', Singaporeans have come to expect that all forms of it need to be 'cheap'.
However, one netizen reframed the situation as follows.
At the risk of getting yelled at, I do believe that it's not reasonable to expect prices of hawker food not to go up. If doing backbreaking work and toiling long hours as a hawker doesn't give someone the means to live comfortably, then why become one?
While I don't want to pay S$10 for a bowl of wanton mee, there has to be something in the trade to make it worthwhile for new blood to want to continue our hawkers' legacies. Perhaps one day soon, a happy medium can be found between keeping hawker fare affordable, while providing them a reason to take up this trade to preserve our cultural heritage.
$6.50 for 'small' vegetarian bee hoon? Netizens react to rising vegetarian food prices
The post 'Why are you not prepared to pay $5 for wanton mee?' – Minister's comments spark outrage from netizens appeared first on SETHLUI.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Rallygoers protest against ‘appalling' ICE arrest of asylum seeker
PORTLAND, Ore. () — A rally was held in Vancouver Wednesday evening in protest against an Immigration and Customs Enforcement arrest that happened in Portland earlier this week. A woman was seeking asylum at a Portland immigration courthouse on Monday when . Budget cuts threaten Oregon Outdoor School program OJM, a pseudonym she uses for safety reasons, is a 24-year-old transgender woman from Mexico, where she was abducted and raped because of her gender identity and sexual orientation 'at the hands of a dangerous cartel,' said the Portland-based Innnovation Law Lab, representing her. They said she fled to the United States for safety. The law group said she was processed into Tacoma on Monday night. However, they haven't been granted access to her since her transfer. The Innovation Law Lab argued ICE used 'deceptive and unethical practices' to detain OJM and strip her of her due process rights. They said a federal judge has approved their petition to find out why ICE arrested her and they hope to learn those details soon. A small group of protesters gathered in downtown Vancouver to show their support, chanting, 'Immigrants are welcome here.' 'It's so appalling because when we heard about the ICE detention of the young trans woman from Mexico who was just following the rules,' said Rebecca Ketih, who helped organize the rally. The Department of Homeland Security told KOIN 6 News in a statement on Tuesday that they're doing what they've been told to do. DHS said in part, 'ICE is now following the law and placing these illegal aliens in expedited removal, as they always should have been.' 'It's anyone with brown skin. And this young lady was innocent,' said Carolyn Fu, another rallygoer at the Vancouver demonstration. Fu said she is originally from Hawaii and knows what it's like for her people to be discriminated against. Even still, she said the arrest has sent shockwaves through the community and that people are ready to fight. 'Today's rally is going to wrap up, but it's not going to stop. We're continuing. We're going to continue to fight and, and make sure that our representatives are going to look for her and stand up for her, no matter what it takes,' Fu said. Suspect identified in Battle Ground double homicide U.S. Senator Ron Wyden (D-OR) commented on the woman's ICE arrest, saying on Tuesday that he is 'appalled' at what happened. 'As the son of parents who fled Nazi Germany for refuge in America, I'm appalled by Donald Trump's goons arresting a woman in Portland just when she sought refuge in our country from sexual abuse by drug traffickers in Mexico,' in a post on X. KOIN 6 reached out to other Pacific Northwest lawmakers for comment about the arrest and we will post updates if we hear back. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Miami Herald
5 days ago
- Miami Herald
Two patients faced chemo. The one survivor demanded a test to see if it was safe
JoEllen Zembruski-Ruple, while in the care of New York City's renowned Memorial Sloan Kettering Cancer Center, swallowed the first three chemotherapy pills to treat her squamous cell carcinoma on Jan. 29, her family members said. They didn't realize the drug could kill her. Six days later, Zembruski-Ruple went to Sloan Kettering's urgent care department to treat sores in her mouth and swelling around her eyes. The hospital diagnosed oral yeast infection and sent her home, her sister and partner said. Two days later, they said, she returned in agony — with severe diarrhea and vomiting — and was admitted. 'Enzyme deficiency,' Zembruski-Ruple texted a friend. The 65-year-old, a patient advocate who had worked for the National Multiple Sclerosis Society and other groups, would never go home. Covered in bruises and unable to swallow or talk, she eventually entered hospice care and died March 25 from the very drug that was supposed to extend her life, said her longtime partner, Richard Khavkine. Zembruski-Ruple was deficient in the enzyme that metabolizes capecitabine, the chemotherapy drug she took, said Khavkine and Susan Zembruski, one of her sisters. Zembruski-Ruple was among about 1,300 Americans each year who die from the toxic effects of that pill or its cousin, the IV drug fluorouracil known as 5-FU. Doctors can test for the deficiency — and then either switch drugs or lower the dosage if patients have a genetic variant that carries risk. The FDA approved an antidote in 2015, but it's expensive and must be administered within four days of the first chemotherapy treatment. Newer cancer drugs sometimes include a companion diagnostic to determine whether a drug works with an individual patient's genetics. But 5-FU went on the market in 1962 and sells for about $17 a dose; producers of its generic aren't seeking approval for toxicity tests, which typically cost hundreds of dollars. Doctors have only gradually understood which gene variants are dangerous in which patients, and how to deal with them, said Alan Venook, a colorectal and liver cancer specialist at the University of California-San Francisco. By the time Zembruski-Ruple's doctors told her she had the deficiency, she had been on the drug for eight days, said Khavkine, who watched over his partner with her sister throughout the seven-week ordeal. Khavkine said he 'would have asked for the test' if he had known about it, but added 'nobody told us about the possibility of this deficiency.' Zembruski-Ruple's sister also said she wasn't warned about the fatal risks of the chemo, or told about the test. 'They never said why they didn't test her,' Zembruski said. 'If the test existed, they should have said there is a test. If they said, 'Insurance won't cover it,' I would have said, 'Here's my credit card.' We should have known about it.' Guidance moves at a glacial pace Despite growing awareness of the deficiency, and an advocacy group made up of grieving friends and relatives who push for routine testing of all patients before they take the drug, the medical establishment has moved slowly. A panel of the National Comprehensive Cancer Network, or NCCN — specialists from Sloan Kettering and other top research centers — until recently did not recommend testing, and the FDA does not require it. In response to a query from KFF Health News about its policy, Sloan Kettering spokesperson Courtney Nowak said the hospital treats patients 'in accordance with NCCN guidelines.' She said the hospital would not discuss a patient's care. On Jan. 24, the FDA issued a warning about the enzyme deficiency in which it urged health care providers to 'inform patients prior to treatment' about the risks of taking 5-FU and capecitabine. On March 31 — six days after Zembruski-Ruple's death — the network's expert panel for most gastrointestinal cancers took a first step toward recommending testing for the deficiency. Worried that President Donald Trump's FDA might do nothing, Venook said, the panel — whose guidance shapes the practices of oncologists and health insurers — recommended that doctors consider testing before dosing patients with 5-FU or capecitabine. However, its guidance stated that 'no specific test is recommended at this time,' citing a lack of data to 'inform dose adjustments.' Sloan Kettering 'will consider this guidance in developing personalized treatment plans for each patient,' Nowak told KFF Health News. The new NCCN guidance was 'not the blanket recommendation we were working toward, but it is a major step toward our ultimate goal,' said Kerin Milesky, a public health official in Brewster, Massachusetts, who's part of an advocacy group for testing. Her husband, Larry, died two years ago at age 73 after a single treatment of capecitabine. European drug regulators began urging oncologists to test patients for deficiency in May 2020. Patients with potentially risky genetics are started on a half-dose of the cancer drug. If they suffer no major toxicity, the dose is increased. A lifesaving ultimatum? Emily Alimonti, a 42-year-old biotech salesperson in upstate New York, chose that path before starting capecitabine treatment in December. She said her doctors — including an oncologist at Sloan Kettering — told her they didn't do deficiency testing, but Alimonti insisted. 'Nope,' she said. 'I'm not starting it until I get the test back.' The test showed that Alimonti had a copy of a risky gene variant, so doctors gave her a lower dose of the drug. Even that has been hard to tolerate; she's had to skip doses because of low white blood cell counts, Alimonti said. She still doesn't know whether her insurer will cover the test. Around 300,000 people are treated with 5-FU or capecitabine in the United States each year, but its toxicity could well have prevented FDA approval were it up for approval today. Short of withdrawing a drug, however, U.S. regulators have little power to manage its use. And 5-FU and capecitabine are still powerful tools against many cancers. At a January workshop that included FDA officials and cancer specialists, Venook, the NCCN panel's co-chair, asked whether it was reasonable to recommend that doctors obtain a genetic test 'without saying what to do with the result.' But Richard Pazdur, the FDA's top cancer expert, said it was time to end the debate and commence testing, even if the results could be ambiguous. 'If you don't have the information, how do you have counseling?' he asked. Two months later, Venook's panel changed course. The price of tests has fallen below $300 and results can be returned as soon as three days, Venook said. Doubts about the FDA's ability to further confront the issue spurred the panel's change of heart, he said. 'I don't know if FDA is going to exist tomorrow,' Venook told KFF Health News. 'They're taking a wrecking ball to common sense, and that's one of the reasons we felt we had to go forward.' On May 20, the FDA posted a Federal Register notice seeking public input on the issue, a move that suggested it was considering further action. Venook said he often tests his own patients, but the results can be fuzzy. If the test finds two copies of certain dangerous gene variants in a patient, he avoids using the drug. But such cases are rare — and Zembruski-Ruple was one of them, according to her sister and Khavkine. Many more patients have a single copy of a suspect gene, an ambiguous result that requires clinical judgment to assess, Venook said. A full-gene scan would provide more information but adds expense and time, and even then the answer may be murky, Venook said. He worries that starting patients on lower doses could mean fewer cures, especially for newly diagnosed colon cancer patients. Power should rest with patients Scott Kapoor, a Toronto-area emergency room physician whose brother Anil, a much-loved urologist and surgeon, died of 5-FU toxicity at age 58 in 2023, views Venook's arguments as medical paternalism. Patients should decide whether to test and what to do with the results, he said. 'What's better — don't tell the patient about the test, don't test them, potentially kill them in 20 days?' he said. 'Or tell them about the testing while warning that potentially the cancer will kill them in a year?' 'People say oncologists don't know what to do with the information,' said Karen Merritt, whose mother died after an infusion of 5-FU in 2014. 'Well, I'm not a doctor, but I can understand the Mayo Clinic report on it.' The Mayo Clinic recommends starting patients on half a dose if they have one suspect gene variant. And 'the vast majority of patients will be able to start treatment without delays,' Daniel Hertz, a clinical pharmacologist from the University of Michigan, said at the January meeting. Some hospitals began testing after patients died because of the deficiency, said Lindsay Murray, of Andover, Massachusetts, who has advocated for widespread testing since her mother was treated with capecitabine and died in 2021. In some cases, Venook said, relatives of dead patients have sued hospitals, leading to settlements. Kapoor said his brother — like many patients of non-European origin — had a gene variant that hasn't been widely studied and isn't included in most tests. But a full-gene scan would have detected it, Kapoor said, and such scans can also be done for a few hundred dollars. The cancer network panel's changed language is disappointing, he said, though 'better than nothing.' In video tributes to Zembruski-Ruple, her friends, colleagues, and clients remembered her as kind, helpful, and engaging. 'JoEllen was beautiful both inside and out,' said Barbara McKeon, a former colleague at the MS Society. 'She was funny, creative, had a great sense of style.' 'JoEllen had this balance of classy and playful misbehavior,' psychotherapist Anastatia Fabris said. 'My beautiful, vibrant, funny, and loving friend JoEllen.' KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.
Time Business News
6 days ago
- Time Business News
Wsq Advanced Excel Course SkillsFuture Approved: What You Need to Know
In today's competitive job market, mastering data skills is more important than ever. Whether you are an analyst, finance professional, project manager, or data enthusiast, Excel remains the backbone of data analysis and reporting in organizations worldwide. However, basic Excel skills no longer suffice — employers are now seeking professionals proficient in advanced Excel functions, automation, and data visualization. For Singaporeans looking to upskill affordably, the WSQ advanced Excel course SkillsFuture approved by the government provides a golden opportunity. In this article, you will learn everything you need to know about this course, how it can boost your career, what to expect from the curriculum, and how to enroll. WSQ stands for Workforce Skills Qualifications — a nationally recognized certification system designed by SkillsFuture Singapore (SSG) to ensure high-quality workforce training. The WSQ advanced Excel course SkillsFuture approved means that this course meets government standards and is eligible for SkillsFuture Credit subsidies. Offered by trusted providers like Intellisoft Training, this course goes beyond basic Excel skills to teach advanced functions such as: Power Query for data transformation and automation Advanced formulas including array formulas and nested IF statements PivotTables and Power Pivot for multidimensional data analysis Macros and VBA programming to automate repetitive tasks Building interactive dashboards and infographics This training is designed for professionals who want to harness Excel's full potential and stand out in their roles. Singaporean citizens and permanent residents can use their SkillsFuture Credits to offset part or all of the course fee, making it a cost-effective way to gain advanced Excel skills without financial strain. Completing this course awards you a WSQ-certified credential, recognized by employers across industries in Singapore. It serves as proof of your expertise and commitment to professional development. Unlike generic online tutorials, this course offers practical, real-world projects designed to solve actual workplace challenges. You will learn how to automate reporting processes, build dashboards, and handle complex datasets. Learn from Microsoft-certified trainers who bring years of corporate and teaching experience. Personalized support ensures you grasp even the most complex topics. Whether you prefer weekday classes, weekends, or online learning, Intellisoft Training provides flexible options to fit your schedule. The WSQ advanced Excel course SkillsFuture curriculum is structured to build your expertise systematically. Here's a detailed breakdown of what you will learn: Deep dive into nested IF statements, IFS, SUMIFS, COUNTIFS INDEX-MATCH combination vs VLOOKUP — best practices Text functions for dynamic data manipulation Date and time functions for scheduling and timelines Introduction to array formulas and Excel's new dynamic arrays Extract, clean, and reshape data from multiple sources Automate repetitive data cleaning tasks Create reusable data import pipelines for efficiency Building complex PivotTables with calculated fields Use Power Pivot to analyze millions of rows Create KPIs and interactive reports Record and edit macros to automate tasks Write VBA scripts to customize Excel functionalities Develop user forms and interactive controls Principles of effective data visualization Create interactive dashboards with slicers and timelines Use charts creatively for impactful presentations Learn from the specialized Infographics & Data Visualization Excel Course This course is ideal for: Financial analysts handling budgeting and forecasting Data analysts and scientists managing large datasets Project managers tracking progress and resources Marketing professionals analyzing campaign data HR executives managing payroll and attendance reports Anyone looking to boost productivity and data skills with Excel 'Joining the WSQ advanced Excel course was the best decision for my career. The SkillsFuture subsidy made it affordable, and the hands-on training helped me automate monthly reports that used to take days.' — Jessica L., Business Analyst 'I moved from an entry-level role to a data executive position after completing this course. The practical assignments prepared me for real challenges at work.' — Kelvin T., Data Executive When you enroll in this course, you also gain access to: Downloadable Excel templates for finance, marketing, and HR Cheat Sheets for advanced formulas and keyboard shortcuts Video tutorials for revision and advanced tips E-books focused on Excel dashboards, automation, and reporting These materials support continuous learning even after the course ends. SkillsFuture is a government initiative to support lifelong learning for Singaporeans. You can use your SkillsFuture credits to pay for this WSQ advanced Excel course, making upskilling affordable. Singapore citizens and permanent residents with SkillsFuture credits in their account can apply for the subsidy when registering for this course. Yes, Intellisoft Training offers both in-person and online modes for this advanced Excel course to suit different learning preferences. The course typically runs for 2-3 days, with flexible schedules on weekdays or weekends. Upon successful completion, you receive a WSQ-certified credential recognized by employers and training institutions. No, the course is designed for learners with intermediate Excel knowledge who want to advance to higher-level skills. Enrolling is easy: Visit the Intellisoft Training homepage Browse through Excel Courses in Singapore Select the WSQ advanced Excel course SkillsFuture approved Register online and apply your SkillsFuture credits during payment Choose your preferred training mode and schedule Completing this advanced Excel course can lead to tangible career growth, including: Increased efficiency in data processing and reporting Enhanced ability to analyze and visualize complex datasets Higher chances of promotion to roles like data analyst, financial analyst, or operations manager Competitive edge in job applications and interviews Recognition through a government-accredited certification With data becoming central to every business decision, advanced Excel skills are no longer optional—they are essential. By enrolling in the WSQ advanced Excel course SkillsFuture approved by Intellisoft Training, you invest in your professional growth with affordable, high-quality education. Gain confidence with powerful Excel tools, automate repetitive work, build impactful dashboards, and showcase your expertise with a respected certification. Whether you're aiming for career advancement or personal skill enhancement, this course is your gateway to data proficiency. Don't wait — empower your career today! TIME BUSINESS NEWS
